eprintid: 10085255
rev_number: 38
eprint_status: archive
userid: 608
dir: disk0/10/08/52/55
datestamp: 2019-11-06 12:06:35
lastmod: 2025-05-15 09:36:47
status_changed: 2020-09-15 16:58:58
type: article
metadata_visibility: show
creators_name: Chan, AHY
creators_name: Horne, R
creators_name: Hankins, M
creators_name: Chisari, C
title: The Medication Adherence Report Scale (MARS-5): a measurement tool for eliciting patients’ reports of non-adherence
ispublished: pub
divisions: UCL
divisions: B02
divisions: C08
divisions: D10
divisions: G11
keywords: adherence, MARS-5, Medication Adherence Report Scale, self-report, validation
note: © 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in anymedium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
abstract: Aims:
This study aimed to develop a questionnaire measure of patients' adherence to medications to elicit patients' report of medication use. The reliability and validity were assessed in patients with hypertension. Additional analyses were performed on other patient groups.

Methods:
Using a cross‐sectional study design, a 10‐item version of the Medication Adherence Report Scale (MARS)© Professor Rob Horne was piloted in two samples of patients receiving treatment for hypertension (n=50 + 178), asthma (n=100) or diabetes (n=100) at hospital outpatient or community clinics in London and the South‐East of England. Following principal components analysis, five items were retained to form the ‘MARS‐5'©Professor Rob Horne. Evaluation comprised internal reliability, test‐retest reliability, criterion‐related validity (relationship with blood pressure control) and construct validity (relationship with patients' beliefs about medicines).

Results:
The MARS‐5 demonstrated acceptable reliability (internal and test‐retest) and validity (criterion‐related and construct validity). Internal reliability (Cronbach's α) ranged from 0.67 to 0.89 across all patient groups; test‐retest reliability (Pearson's r) was 0.97 in Hypertension. Criterion‐related validity was established with more adherent hypertension patients showing better blood‐pressure control (χ2=4.24, df=1, p<0.05). Construct validity with beliefs about medicines was demonstrated with higher adherence associated with stronger beliefs in treatment necessity, and lower concerns.

Conclusions:
The MARS‐5 performed well on several psychometric indicators. It shows promise as an effective self‐report tool for measuring patients' reports of their medication use across a range of health conditions.
date: 2020-07
date_type: published
publisher: Wiley-Blackwell
official_url: https://doi.org/10.1111/bcp.14193
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1716612
doi: 10.1111/bcp.14193
lyricists_name: Chan, Amy Hai Yan
lyricists_name: Horne, Robert
lyricists_id: AHYCH99
lyricists_id: RHORN95
actors_name: Stacey, Thomas
actors_id: TSSTA20
actors_role: owner
full_text_status: public
publication: British Journal of Clinical Pharmacology
volume: 86
number: 7
pagerange: 1281-1288
citation:        Chan, AHY;    Horne, R;    Hankins, M;    Chisari, C;      (2020)    The Medication Adherence Report Scale (MARS-5): a measurement tool for eliciting patients’ reports of non-adherence.                   British Journal of Clinical Pharmacology , 86  (7)   pp. 1281-1288.    10.1111/bcp.14193 <https://doi.org/10.1111/bcp.14193>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10085255/1/Chan_bcp.14193.pdf